Irhythm Technologies (IRTC)
NASDAQ:IRTC
Want to see IRTC full AI Analyst Report?
IRTC Stock Chart & Stats
$125.32
-$0.21(-0.23%)
At close: 4:00 PM EST
$125.32
-$0.21(-0.23%)
Day’s Range― - ―
52-Week Range$104.33 - $212.00
Previous CloseN/A
Volume94.23K
Average Volume (3M)532.89K
Market Cap
$3.47B
Enterprise Value$4.23B
Total Cash (Recent Filing)$549.62M
Total Debt (Recent Filing)$729.29M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Jul 30, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding32,862,408
10 Day Avg. Volume519,126
30 Day Avg. Volume532,887
Financial Highlights & Ratios
PEG Ratio2.07
Price to Book (P/B)37.18
Price to Sales (P/S)7.60
P/FCF Ratio164.50
Enterprise Value/Market Cap1.22
Enterprise Value/Revenue5.37
Enterprise Value/Gross Profit7.57
Enterprise Value/Ebitda881.52
Forecast
1Y Price Target
$177.36Price Target Upside41.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)<0.01
Revenue Forecast (FY)$881.05M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Raised GuidanceSustained high-teens to mid-20s revenue growth and an upward guide signal durable demand for Zio services and expanding clinical adoption. Recurring study-volume driven revenue and strong new-account penetration support scalable top-line growth and create runway for further operating leverage.
High, Expanding Gross MarginsConsistently ~70% gross margins reflect advantaged unit economics from the Zio device plus cloud analytics. Margin expansion from automation, clinical ops efficiencies, and scale is structural, enabling reinvestment in R&D and sales while supporting conversion of revenue growth into durable EBITDA improvement.
Improving Cash Generation & Large Cash BalanceA large cash balance paired with positive trailing‑twelve‑month operating cash flow provides funding flexibility for product development, international expansion, and potential M&A. Improved cash generation reduces near-term financing risk and supports execution of long-term commercialization plans.
Bears Say
Elevated LeverageA debt-heavy capital structure increases financial sensitivity to execution slippage and raises refinancing risk if growth or cash flow weakens. High leverage constrains strategic flexibility and amplifies downside from reimbursement or regulatory setbacks given limited equity cushion.
Ongoing GAAP Net LossesDespite margin progress and positive operating cash flow, persistent GAAP and adjusted net losses mean profitability is not yet established. Continued loss-making restricts free cash flow conversion consistency and leaves long-term returns dependent on sustained margin expansion and scale.
Regulatory & Reimbursement UncertaintyOpen FDA and DOJ reviews plus proposed LCD changes create structural policy risk that could alter reimbursement and clinical workflows. Adverse agency action or unfavorable local coverage determinations would materially affect volumes, pricing, and long-term adoption of the Zio platform.
Irhythm Technologies News
IRTC FAQ
What was Irhythm Technologies’s price range in the past 12 months?
Irhythm Technologies lowest stock price was $104.33 and its highest was $212.00 in the past 12 months.
What is Irhythm Technologies’s market cap?
Irhythm Technologies’s market cap is $3.47B.
When is Irhythm Technologies’s upcoming earnings report date?
Irhythm Technologies’s upcoming earnings report date is Jul 30, 2026 which is in 57 days.
How were Irhythm Technologies’s earnings last quarter?
Irhythm Technologies released its earnings results on Apr 30, 2026. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.659 by $0.229.
Is Irhythm Technologies overvalued?
According to Wall Street analysts Irhythm Technologies’s price is currently Undervalued.
Does Irhythm Technologies pay dividends?
Irhythm Technologies does not currently pay dividends.
What is Irhythm Technologies’s EPS estimate?
Irhythm Technologies’s EPS estimate is -0.05.
How many shares outstanding does Irhythm Technologies have?
Irhythm Technologies has 32,862,408 shares outstanding.
What happened to Irhythm Technologies’s price movement after its last earnings report?
Irhythm Technologies reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.659. Following the earnings report the stock price went down -6.473%.
Which hedge fund is a major shareholder of Irhythm Technologies?
Currently, no hedge funds are holding shares in IRTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Irhythm Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$177.36 (41.53% Upside)
$177.36 (41.53% Upside)
Blogger Sentiment
Bullish
IRTC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 22.0%
Last 30 Days ▼ 22.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.99%
12-Months-Change
Fundamentals
Return on Equity
-20.60%
Trailing 12-Months
Asset Growth
8.67%
Trailing 12-Months
Company Description
Irhythm Technologies
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
IRTC Company Deck
IRTC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was constructive and predominantly positive: the company delivered strong top-line growth (≈26% YoY), meaningful margin expansion (880 bps adjusted EBITDA improvement and +210 bps gross margin), raised full‑year revenue and EBITDA guidance, and showed progress on product, AI, clinical evidence, and international commercialization. Offsetting items include continued GAAP/adjusted net losses (though improved), seasonally negative Q1 free cash flow, elevated operating and litigation-related costs, and outstanding regulatory and legal uncertainties (FDA warning letter, DOJ CID) plus potential coverage ambiguity from proposed LCD language. On balance, the operational and commercial positives materially outweigh the remaining execution and regulatory risks.View all IRTC earnings summariesIRTC Stock 12 Month Forecast
Average Price Target
$177.36
▲(41.53% Upside)
Technical Analysis
Ownership Overview
1.85% Insiders
32.79% Mutual Funds
36.74% Other Institutional Investors
13.73% Public Companies and
Individual Investors